Back to Search
Start Over
BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses.
- Source :
- British Journal of Haematology; Mar2022, Vol. 196 Issue 6, p1329-1333, 5p
- Publication Year :
- 2022
-
Abstract
- Summary: This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer‐BioNTech) COVID‐19 vaccine booster in 44 B‐cell non‐Hodgkin lymphoma (B‐NHL) patients who failed to respond to two prior doses [42 previously exposed to anti‐CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti‐CD20 moAb (>6 months) and diagnosis of aggressive lymphoma compared to other, incurable B‐NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B‐NHL that completed anti‐CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion. [ABSTRACT FROM AUTHOR]
- Subjects :
- BOOSTER vaccines
NON-Hodgkin's lymphoma
COVID-19 vaccines
SEROCONVERSION
VACCINES
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 196
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 155835526
- Full Text :
- https://doi.org/10.1111/bjh.18029